Arkolith/Insider Trading/TARS/Form 4

Azamian Bobak R.

President/CEO and Board Chair, DirectorTarsus Pharmaceuticals, Inc. (TARS) · full profile →Form 4 · filed Mar 17, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)66K——68K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)11K—$00
Mar 15, 2026Option exercise(M)17K—$017K
Mar 15, 2026Option exercise(M)23K—$046K
Mar 15, 2026Option exercise(M)15K—$045K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001827672-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML